Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Human CD27 Ligand/TNFSF7 ELISA Kit

Click to view available options
Quantity:
5 x 96 Tests
96 Tests
Description
Human CD27 Ligand/TNFSF7 quantitates human CD27 Ligand/TNFSF7 in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human CD27 Ligand/TNFSF7.
The protein encoded by this gene is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for TNFRSF27/CD27. It is a surface antigen on activated, but not on resting, T and B lymphocytes. It induces proliferation of costimulated T cells, enhances the generation of cytolytic T cells, and contributes to T cell activation. This cytokine is also reported to play a role in regulating B-cell activation, cytotoxic function of natural killer cells, and immunoglobulin synthesis.

Specifications
Specifications
Accession Number | CD27 ligand; Cd27l; CD27-L; CD27LG; CD70; CD70 antigen; Cd70 molecule; Ki-24 antigen; surface antigen CD70; Tnfsf7; TNLG8A; tumor necrosis factor (ligand) superfamily, member 7; tumor necrosis factor ligand 8 A; tumor necrosis factor ligand superfamily member 7 |
Assay Range | 0.3 to 70 ng/mL |
Assay Sensitivity | 0.3 ng/mL |
Conjugate | HRP |
Product Type | ELISA |
Sample Type | Plasma, Serum, Supernatant |
For Use With (Equipment) | Colorimetric Microplate Reader |
Gene ID (Entrez) | 970 |
Gene Symbol | Cd70 |
Interassay CV | <12% |
Show More |
Safety and Handling
WARNING: Reproductive Harm - www.P65Warnings.ca.gov
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction